Literature DB >> 4183973

Impaired leucotactic responsiveness in a child with recurrent infections.

P A Ward, R J Schlegel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4183973     DOI: 10.1016/s0140-6736(69)92699-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  26 in total

1.  [Granulocyte dysfunction. Part II. Secondary defects. (authors transl)].

Authors:  D Niethammer; A Wildfeuer; E Kleihauer; O Haferkamp
Journal:  Klin Wochenschr       Date:  1975-08-15

2.  Disorders of neutrophil function. Defects in the early stages of the phagocytic process.

Authors:  P J Edelson; D P Stites; S Gold; H H Fudenberg
Journal:  Clin Exp Immunol       Date:  1973-01       Impact factor: 4.330

Review 3.  Immunological deficiency and impaired resistance to infection.

Authors:  K W Walton
Journal:  Br Med J       Date:  1972-02-19

Review 4.  Activities of the neutrophil polymorph.

Authors:  D B Brewer
Journal:  Br Med J       Date:  1972-05-13

Review 5.  Chemotaxis and its significance for leucocyte accumulation.

Authors:  H U Keller
Journal:  Agents Actions       Date:  1972-06

Review 6.  Leukotaxis and leukotactic disorders. A review.

Authors:  P A Ward
Journal:  Am J Pathol       Date:  1974-12       Impact factor: 4.307

Review 7.  Infectious diseases: annual review of significant publications.

Authors:  H A Reimann
Journal:  Postgrad Med J       Date:  1970-05       Impact factor: 2.401

Review 8.  The role of phagocyte function in resistance to infection.

Authors:  R I Lehrer
Journal:  Calif Med       Date:  1971-06

9.  Defective granulocyte chemotaxis in the Chediak-Higashi syndrome.

Authors:  R A Clark; H R Kimball
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808

10.  Abnormal bactericidal, metabolic, and lysosomal functions of Chediak-Higashi Syndrome leukocytes.

Authors:  R K Root; A S Rosenthal; D J Balestra
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.